Guerbet: sales growth of 4% by 2023

(CercleFinance.com) - Guerbet posted annual sales of E785.
7m, up 4.3% on a reported basis. At constant exchange rates and excluding Intrasense, consolidated since 1 January, organic growth was 5.9%.

Perfectly in line with the announced target, this fine performance was fuelled by both higher volumes and positive price effects, the specialist in contrast products and solutions for medical imaging says.

Guerbet estimates that its restated 2023 EBITDA margin will be higher than the 11% initially anticipated. For 2024, it anticipates organic sales growth in excess of 8% and an adjusted EBITDA margin above that of 2021 (14.4%).


Copyright (c) 2024 CercleFinance.com. All rights reserved.